We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+44.04%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$333M
AUM Growth
+$98M
Cap. Flow
+$16.1M
Cap. Flow %
4.84%
Top 10 Hldgs %
83.38%
Holding
25
New
3
Increased
4
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
SLN
Silence Therapeutics
SLN
+$22.2M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.6M
3
ALLK
Allakos
ALLK
+$6.88M
4
KURA icon
Kura Oncology
KURA
+$2.79M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$2.08M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$13.9M
2
GERN icon
Geron
GERN
+$6.67M
3
ETNB
89bio
ETNB
+$3.65M
4
VRDN icon
Viridian Therapeutics
VRDN
+$2.7M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$2.67M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$69.6M 20.87%
3,877,903
+963,653
+33% +$12.6M
COGT icon
2
Cogent Biosciences
COGT
$6.02B
$51.9M 15.58%
3,481,042
– –
GERN icon
3
Geron
GERN
$970M
$28.4M 8.5%
12,115,926
-2,980,416
-20% -$6.67M
VRDN icon
4
Viridian Therapeutics
VRDN
$2.61B
$23.9M 7.16%
1,164,000
-150,000
-11% -$2.7M
SLN
5
Silence Therapeutics
SLN
$834M
$21.1M 6.34%
+2,104,875
New +$22.2M
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
$20.7M 6.2%
5,905,400
– –
KURA icon
7
Kura Oncology
KURA
$1.13B
$18.4M 5.53%
1,348,642
+181,000
+16% +$2.79M
ACRS icon
8
Aclaris Therapeutics
ACRS
$885M
$18M 5.41%
1,144,939
– –
JBIO
9
Jade Biosciences
JBIO
$1.33B
$15.9M 4.77%
27,416
+2,000
+8% +$1.34M
TRDA icon
10
Entrada Therapeutics
TRDA
$273M
$10.1M 3.04%
642,189
-21,505
-3% -$273K
ALLK
11
DELISTED
Allakos
ALLK
$10.1M 3.02%
+1,643,500
New +$6.88M
AKUS
12
DELISTED
Akouos Inc
AKUS
$9.13M 2.74%
1,350,006
– –
TYRA icon
13
Tyra Biosciences
TYRA
$1.49B
$8.31M 2.49%
945,707
+49,289
+5% +$451K
MLTX icon
14
MoonLake Immunotherapeutics
MLTX
$1.28B
$7.76M 2.33%
1,000,000
– –
MRUS
15
DELISTED
Merus
MRUS
$6.01M 1.8%
300,000
– –
TNGX icon
16
Tango Therapeutics
TNGX
$3.94B
$4.24M 1.27%
1,172,250
– –
DNTH icon
17
Dianthus Therapeutics
DNTH
$5.92B
$3M 0.9%
132,758
– –
ZLAB icon
18
Zai Lab
ZLAB
$2.93B
$2.49M 0.75%
72,777
-22,223
-23% -$951K
MDGL icon
19
Madrigal Pharmaceuticals
MDGL
$12.3B
$1.95M 0.58%
+30,000
New +$2.08M
ALPN
20
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.83M 0.55%
254,569
-323,691
-56% -$2.67M
ELEV
21
DELISTED
Elevation Oncology
ELEV
$627K 0.19%
555,000
– –
ANAB icon
22
AnaptysBio
ANAB
$1.67B
– –
-58,515
Closed -$1.19M
ETNB
23
DELISTED
89bio
ETNB
– –
-1,133,196
Closed -$3.65M
PRDS
24
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-59,039
Closed -$181K
KDNY
25
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-796,460
Closed -$13.9M

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return

TCG Crossover Management's Q3 2022 Portfolio in Review

As of Q3 2022, TCG Crossover Management held 25 positions worth $333M, up 42% from $235M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

TCG Crossover Management deployed $16.1M of net new capital in Q3 2022, opening 3 new positions and adding to 4 existing holdings. Its largest new stake was Silence Therapeutics: 2,104,875 shares worth $21.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Geron, an estimated $6.67M trimmed.

  • TCG Crossover Management's largest Q3 2022 buy was Silence Therapeutics: 2,104,875 shares worth $21.1M.
  • TCG Crossover Management added most to IVERIC bio, Inc. Common Stock in Q3 2022, an estimated $12.6M increase.
  • TCG Crossover Management's biggest Q3 2022 reduction was Geron, cutting an estimated $6.67M.
  • TCG Crossover Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $13.9M.
  • TCG Crossover Management's ten largest holdings make up 83% of its $333M portfolio in Q3 2022.
  • TCG Crossover Management opened 3 new positions and closed 4 in Q3 2022.
  • TCG Crossover Management's portfolio value rose 42% quarter-over-quarter to $333M.

Based on TCG Crossover Management's 13F filing for Q3 2022, filed 14 Nov 2022.